- Home
- CNF vs IMMX Comparison
CNF vs IMMX Comparison
Compare CNF & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNF
- IMMX
- Stock Information
- Founded
- CNF 1999
- IMMX 2014
- Country
- CNF China
- IMMX United States
- Employees
- CNF N/A
- IMMX N/A
- Industry
- CNF Finance: Consumer Services
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- CNF Finance
- IMMX Health Care
- Exchange
- CNF Nasdaq
- IMMX Nasdaq
- Market Cap
- CNF 59.0M
- IMMX 61.1M
- IPO Year
- CNF 2018
- IMMX 2021
- Fundamental
- Price
- CNF $1.18
- IMMX $2.04
- Analyst Decision
- CNF
- IMMX Strong Buy
- Analyst Count
- CNF 0
- IMMX 1
- Target Price
- CNF N/A
- IMMX $7.00
- AVG Volume (30 Days)
- CNF 57.9K
- IMMX 135.6K
- Earning Date
- CNF 02-27-2025
- IMMX 11-12-2024
- Dividend Yield
- CNF N/A
- IMMX N/A
- EPS Growth
- CNF N/A
- IMMX N/A
- EPS
- CNF 0.24
- IMMX N/A
- Revenue
- CNF $109,788,152.00
- IMMX N/A
- Revenue This Year
- CNF N/A
- IMMX N/A
- Revenue Next Year
- CNF $13.09
- IMMX $200.00
- P/E Ratio
- CNF $4.92
- IMMX N/A
- Revenue Growth
- CNF 12.99
- IMMX N/A
- 52 Week Low
- CNF $0.81
- IMMX $1.26
- 52 Week High
- CNF $2.84
- IMMX $5.73
- Technical
- Relative Strength Index (RSI)
- CNF 60.31
- IMMX 46.03
- Support Level
- CNF $1.07
- IMMX $2.15
- Resistance Level
- CNF $1.16
- IMMX $2.49
- Average True Range (ATR)
- CNF 0.10
- IMMX 0.19
- MACD
- CNF 0.02
- IMMX -0.04
- Stochastic Oscillator
- CNF 81.08
- IMMX 23.70
About CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.